Phase 2Completed
Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment (COGICRehab)
Evaluation de l'efficacité de la Galantamine Versus Placebo associée à Une Revalidation Neuropsychologique Chez Des Patients présentant un Trouble Cognitif après un Premier Infarctus cérébral : étude en Neuroimagerie Fonctionnelle
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France (Government)
- Enrolment
- 47 enrolled
- Conditions
- Stroke; Cognitive Impairment
- Interventions
- Galantamine; placebo
- Ages
- adults, older adults
- Registry
- NCT01508494
From the registry
The investigators would like to conduct a double blind placebo-controlled prospective study to show the impact of a treatment combining a specific cognitive rehabilitation program and acetylcholinesterase inhibitors on executive function of young patients 3 months after a first symptomatic stroke. The secondary objectives will be to assess cognitive changes performance (executive but also non trained functions such as memory) before and after treatments and treatment effect on activity of daily living and on quality of life. The main objective of this study is to show the impact of this combined treatment on brain activation maps in VCI-ND patients in the post-acute phase (3 months) after a stroke. Treatment effect will be assessed by functional MRI (fMRI) while patients will be performing a specific executive task. The investigators hypothesize that the specific rehabilitation associated with acetylcholinestrase inhibitors treatment will focalize cerebral activation observed in fMRI, improve executive functions specifically, improve non trained cognitive functions (generalization…
Primary outcomes
- fMRI